Bartosz Chmielowski
Experienced in Lung Nodules

Dr. Bartosz Chmielowski

Hematology Oncology | Hematology | Oncology
The Regents Of The University Of California
200 Medical Plz, 
Los Angeles, CA 
 (1324.1 mi)
Offers Telehealth
Experienced in Lung Nodules
The Regents Of The University Of California
200 Medical Plz, 
Los Angeles, CA 
 (1324.1 mi)
OverviewInsuranceLocationsClinical Research

Overview

Bartosz Chmielowski is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Chmielowski and is rated as an Experienced provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Melanoma, Adult Soft Tissue Sarcoma, Liposarcoma, Vulvectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 120 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Ronald Reagan UCLA Medical Center
Santa Monica - UCLA Med Ctr & Orthopaedic Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
200 Medical Plz, Los Angeles, CA 90095
Other Locations
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
11303 W Washington Blvd, Suite 100, Los Angeles, CA 90066
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
2020 Santa Monica Blvd, Suite 580, Santa Monica, CA 90404
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
900 Weyburn Place, Suite 14 171, Los Angeles, CA 90095

Additional Areas of Focus

Dr. Chmielowski has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drugs: LXH254, LTT462, Trametinib, Ribociclib
Study Phase: Phase 2
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2024
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Enrollment Status: Terminated
Publish Date: August 23, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Pembrolizumab
Study Phase: Phase 2
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
Enrollment Status: Terminated
Publish Date: April 16, 2024
Intervention Type: Biological
Study Drug: ITIL-168
Study Phase: Phase 2
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2024
Intervention Type: Drug
Study Drugs: Anlotinib, Decarbazine
Study Phase: Phase 3
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological
Study Drugs: MGD013, MGD013+Margetuximab
Study Phase: Phase 1
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Suspended
Publish Date: August 18, 2022
Intervention Type: Biological
Study Drugs: NeoTCR-P1 Adoptive Cell Therapy, Nivolumab, IL-2
Study Phase: Phase 1
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1
An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma
An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma
Enrollment Status: Terminated
Publish Date: September 03, 2020
Intervention Type: Biological, Other
Study Phase: Phase 1
View 16 Less Clinical Trials

120 Total Publications

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024.
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 17, 2024
Similar Doctors
Advanced in Lung Nodules
Dr. Shahrooz Eshaghian
Hematology Oncology | Hematology | Oncology
Advanced in Lung Nodules
Dr. Shahrooz Eshaghian
Hematology Oncology | Hematology | Oncology

Los Angeles Hematology-Oncology Medical Group

2080 Century Park E, Suite 1005, 
Los Angeles, CA 
 (2.1 mi)
310-229-3555
Languages Spoken:
English
Offers Telehealth

Shahrooz Eshaghian is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Eshaghian and is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Multiple Myeloma, Bone Tumor, Deep Vein Thrombosis, Anemia, and Bone Marrow Aspiration.

Advanced in Lung Nodules
Dr. Youram Nassir
Hematology Oncology | Hematology
Advanced in Lung Nodules
Dr. Youram Nassir
Hematology Oncology | Hematology
5901 W Olympic Blvd, Suite 505, 
Los Angeles, CA 
 (5.0 mi)
323-930-2324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Youram Nassir is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Nassir and is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Bone Tumor, Multiple Myeloma, Anemia, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Aspiration.

Experienced in Lung Nodules
Dr. Mihran H. Shirinian
Hematology Oncology | Oncology | Hematology
Experienced in Lung Nodules
Dr. Mihran H. Shirinian
Hematology Oncology | Oncology | Hematology
1505 Wilson Ter, Suite 340, 
Glendale, CA 
 (13.7 mi)
818-543-7574
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mihran Shirinian is a Hematologist Oncology specialist and an Oncologist in Glendale, California. Dr. Shirinian and is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Acute Erythroid Leukemia (AEL), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Colorectal Cancer.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile